G. Atkins

发表

Expression of fibrillins and other microfibril-associated proteins in human bone and osteoblast-like cells.

A. Evdokiou, S. Kitahama, G. Atkins, 2000, Bone.

Enhanced Apoptosis of Soft Tissue Sarcoma Cells with Chemotherapy: A Potential New Approach Using Trail

A. Evdokiou, M. Clayer, G. Atkins, 2001, Journal of orthopaedic surgery.

Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy

A. Evdokiou, G. Atkins, A. Labrinidis, 2003, British Journal of Cancer.

143 osteosarcoma cells to Apo 2 L / TRAIL-induced apoptosis is mediated by acquisition of DcR 2 / TRAIL-R 4 expression : resensitisation with chemotherapy

A. Evdokiou, A. Labrinidis, S. Hay, 2003 .

Sensitivity of fresh isolates of soft tissue sarcoma, osteosarcoma and giant cell tumour cells to Apo2L/TRAIL and doxorubicin.

A. Evdokiou, M. Clayer, S. Graves, 2004, International journal of oncology.

Evidence for osteocyte-mediated bone-matrix degradation associated with periprosthetic joint infection (PJI)

Y. Starczak, D. Yang, G. Atkins, 2021, European Cells and Materials.

Osteoprotegerin (OPG) is localized to the Weibel‐Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor

A. Zannettino, L. To, J. Gamble, 2005, Journal of cellular physiology.

The metabolism of 25-(OH)vitamin D3 by osteoclasts and their precursors regulates the differentiation of osteoclasts

H. Morris, D. Findlay, G. Atkins, 2010, The Journal of Steroid Biochemistry and Molecular Biology.

Calcitonin decreases the adherence and survival of HEK-293 cells by a caspase-independent mechanism.

A. Evdokiou, D. Findlay, L. Raggatt, 2002, The Journal of endocrinology.

A case of autosomal dominant osteopetrosis type II with a severe bone phenotype but no amino acid converting mutation in the CLCN7 gene

N. Ito, A. Evdokiou, P. Roschger, 2021, medRxiv.

Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector

G. Atkins, B. Sheahan, M. Fleeton, 2005, Gene Therapy.

Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12

G. Atkins, C. P. Chikkanna-Gowda, B. Sheahan, 2005, Gene Therapy.

Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice

G. Atkins, B. Sheahan, M. Fleeton, 2007, Gene Therapy.

Hydrostatic pressure mimicking diurnal spinal movements maintains anabolic turnover in bovine nucleus pulposus cells in vitro.

Y. Starczak, D. Yang, G. Atkins, 2021, European cells & materials.